Evaluation of Cyfra 21-1 as a diagnostic tool in lung cancer

Journal of Applied Sciences Research

Volumn 5, Issue 9, 2009, Pages 1195-1201

  EL Nabi, Esmat Ali Abd ^a   EL Din Gomaa, Nada Ezz ^b   EL Karim Abo Zeid, Amany Atef ^a   Kantoush, Nagwa Abdel Aziz ^b   Ahmed, Mohammed Mahmoud ^b   Bushra, Safwat Samir ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Adenocarcinoma; Cytokeratin 19 Cyfra 21 1; Lung cancer; Non small cell lung cancer; Small cell lung cancer; Squamous cell carcinoma; Tumor markers

Indexed keywords

EID: 77949326949     PISSN: 1816157X     EISSN: 1819544X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ebert, W. and T. Muley, 1996. Cyfra 21-1 in the follow up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticncer Res., 19: 2669-2672.
2. Kulpa, J., E. Wojcik, M. Reinfuss and L. Kolodziejski, 2002. Carcinoembryonic antigen, Squamous cell carcinoma antigen, Cyfra 21-1, and neurone-specific enolase in squamous cell lung cancer patients. Clin Chem., 48: 1931-1937.
3. Molina, R., X. Filella, J.M. Auge, R. Fuentes, I. Bover, J. Rifa, V. Moreno, Canals N. E.,Vinolas, A. Marquez, Barreiro, J. Borras and P. Viladiu, 2003. (CEA, CA125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis; Comparison with the main clinical and pathological prognostic factors. Tumor Biol., 2003. 24: 209-18.
4. Malati, T., 2007. Tumor markers: an overview. Indian Journal of Clinical Biochemistry, 22(2): 17-31.
5. Hatzakisa, K.D., M.E. Froudarakisa, D. Bourosa, N. Tzanakisa, N. Karkavitsasb and N.M. Siafakasa, 2002. Prognostic value of serum tumor markers in patients with lung cancer. Respiration, 69: 25-29.
6. Nakayama, M., H. Satoh, H. Ishikawa, M. Fujiwara, H. Kamma, M. Ohtsuka and K. Sekizawa, 2003. Cytokeratin 19 fragment in patients with non malignant respiratory diseases. Chest., 123: 2001-2006.
7. Barak, V., H. Goike, K.W. Panaretakis and R. Einarson, 2004. Clinical utility of cytokeratins as tumor markers. Clin Biochem., 37(7): 529-540.
8. Abd El Ghaffar, M., E.A. Abd El Nabi and A.A. Ali, 1999. The value of Carcinoembryonic antigen (CEA) and Cytokeratin 19 fragments (Cyfra 21-1) in diagnosis of pleural effusion. Egyptian J Chest Dis and Tuberc, 48(1): 85-90.
9. Shitrit, D., B. Zingerman, A.B. Shitrit, D. Shlomi, M.R. Kramer, 2005. Diagnostic Value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 Assays in Pleural Effusions: Analysis of 116 Cases and Review of the Literature. The Oncologist, 10(7): 501-507, doi:10.1634/theoncologist.10-7-501
10. Pujol, J.L., O. Molinier, W. Ebert, J.P. Daures, F. Barlesi, G. Buccheri, M. Panesmans, E. Quoix, D. Moro-Sibilot, M. Szturmowicz, J.M. Brechot, T. Muley and J. Grenier, 2004. CYFRA 21- 1 is a prognostic determinant in non-small cell lung cancer. Br J Cancer, 90:2097-2105.
11. Muley, T., H. Dieemann and W. Ebert, 2004. Cyfra 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res., 24: 1953-1956.
12. Vollmer, R.T., R. Govindan, S.L. Graziano, G. Gamble, J. Garst, M.J. Kelly and R.H. Christenson, 2003. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res., 9: 1728-33.
13. Rastel, D., E. Comoy, P.H. Levasseur and S. Fatal, 1993. Pre and Postopertive values of Cyfra 21-1, CEA, SCCA, TPA and NSE in primay lung cancer. Eur J Cancer, 29(6): 247S.
14. Yoshimasu, T., S. Maebeya, T. Suzuma, T. Bessho, H. Tanino, J. Arimoto, T. Sakurai and Y. Naito, 1999. Disappearance curves for tumor markers after resection of intrathoracic malignancies. Int J Biol Markers, 14: 99-105.
15. Tan, Y., P. Zhang, C. Zheng, 1999. Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer. Zhonghua Zhong Liu Za Zhi., 21(4): 287-9.
16. Mountain, C.F., 1997. special report: Revisions in the International System for Staging Lung Cancer. CHEST: 111: 1710-17.
17. Karnak, D., G. Ulubay, O. Kayakan, S. Beder, E. Ibis and G. Oflaz, 2001. Evaluation of Cyfra 21-1: A potential tumor marker for non-small cell lung carcinoma. Lung, 179: 57-65.
18. Oremek, G.M., U.B. Seiffert, R. Siekmeier, R. Kirsten, 1995. Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases. Med Klin (Munich), 90(1): 23-6.
19. Mumbark, P.P., A.S. Raste and M.S. Ghadge, 2006. Significance of tumor markers in lung cancer. Indian Journal of Clinical Biochemistry, 21(1): 173-176.
20. Schneider, J., H.G. Velcovsky, H. Morr, N. Katz, K. Neu and E. Eigenbrodt, 2000. Comparison of the tumor markers M2-PK, CEA, Cyfra 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res., 20(6): 5053-5058.
21. Pujol, J.L., J. Grenier, E. Parrat, M. Lehmann, T. Lafontaine, X. Quantin and F.B. Michel, 1996. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21- 1 and TPS. Am J Respir Crit Care Med., 154(3): 725-733.
22. Sun, S.S., J.F. Hsieh, S.C. Tsai, Y.J. Ho, J.K. Lee and C.H. Kao, 2000. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of reccurence of squamous cell lung carcinoma. Am J Clin Oncol., 23: 241-3.
23. Tas, F., A. Aydiner, E. Topuz, V. Yasaserver, A. Karadeniz and P. Saip, 2000. CEA, squamous cell carcinoma antigen, and Cyfra 21-1 in squamous cell lung cancer. J EXP Clin Cancer Res., 19(4): 477-81.
24. Buccheri, G., P. Torchio and D. Ferrigno, 2003. Clinical Equivalence of Two Cytokeratin Markers in Non-small Cell lung Cancer. A study of TPA and Cutokeratin 19 fragment. Chest, 124: 622-632.
25. Kinoshita, M., H. Watanabe, M. Ichiki, S. Sumita, Y. Okubo, M. Matsunami, H. Furuno, T. Shiraishi, T. Rikimaru, K. Oizumi, 1998. Cyfra 21-1 as a marker of lung cancer. Kurume Med J., 45(1): 7-9.
26. Abd El Ghaffar, M., S. Ibrahim and N. Aldanasory, 1999. Carcinembryonic antigen (CEA), Carbohydrate antigen (CA15-3) and Cytokeratin 19 fragment (Cyfra 21-1). A tumor marker panel study in diagnosis of primary pulmonary malignancy. Egyptian J Chest Dis and Tuberc, 48(1): 91-99.